Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Arteriogenesis and Angiogenesis: Molecular Mechanisms and Therapies
share announcement

Arteriogenesis and Angiogenesis: Molecular Mechanisms and Therapies

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 5320

Special Issue Editor

Dr. Michael Rehman

E-Mail Website
Guest Editor
Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT 06520, USA
Interests: kidney disease; cardiovascular; fibrosis; cancer

Special Issue Information

Dear Colleagues,

This Special Issue of Biomedicines is dedicated to presenting new and interesting findings related to arteriogenesis. Studies in the past several years have shown the importance of the process of arteriogenesis in cardiovascular disorders, peripheral artery disorders, cerebral ischemia, renovascular disorders, diabetes, and cancer, among others. It is a complex process defined by the enlargement of small arterioles with little or no blood flow to larger conducting arteries covered with smooth muscle cells and thereby restoring blood flow to tissues with occluded arteries. The role of inflammatory cells, especially monocytes, cannot be overstated in the early stages of remodeling. However, whether similar mechanisms occur in all tissues during this process is far from clear. Arteriogenesis has also been reported to occur during development with the help of genetic lineage-tracing approaches, and we are still learning about the differences between developmental and adult arteriogenesis mechanisms. Understanding all these mechanisms presents enormous challenges. The availability of new approaches of single-cell analysis, genetic lineage-tracing methods and organoid models, among others, will likely increase our understanding on several fronts. Furthermore, this knowledge will eventually benefit the goal of therapeutic arteriogenesis.

This Special Issue therefore seeks submissions of primary research articles and reviews on previously studied and novel aspects of arteriogenesis. The topics include, but are not limited to, mechanisms during development and disease, new and emerging models and methods related to studying arteriogenesis, reviews of clinical trials, and innovations in translation from bench to bedside.

Dr. Michael Rehman
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genetic lineage tracing
  • differentiation markers
  • arterio-venous differentiation
  • shear stress
  • extracellular matrix
  • smooth muscle cells
  • vascular factors
  • myocardial infarction
  • leukocytes

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

33 pages, 11363 KiB  
Article
Patient-Derived Primary Cancer-Associated Fibroblasts Mediate Resistance to Anti-Angiogenic Drug in Ovarian Cancers
by Raed Sulaiman, Pradip De, Jennifer C. Aske, Xiaoqian Lin, Adam Dale, Nischal Koirala, Kris Gaster, Luis Rojas Espaillat, David Starks and Nandini Dey
Biomedicines 2023, 11(1), 112; https://doi.org/10.3390/biomedicines11010112 - 01 Jan 2023
Cited by 6 | Viewed by 2917
Abstract
Ovarian cancers rank first in both aggressiveness and dismal prognosis among gynecological neoplasms. The poor outcome is explained by the fact that most patients present with late-stage disease and progress through the first line of treatment. Ovarian neoplasms, especially epithelial ovarian cancers, are [...] Read more.
Ovarian cancers rank first in both aggressiveness and dismal prognosis among gynecological neoplasms. The poor outcome is explained by the fact that most patients present with late-stage disease and progress through the first line of treatment. Ovarian neoplasms, especially epithelial ovarian cancers, are diagnosed at advanced/metastatic stages, often with a high angiogenesis index, one of the hallmarks of ovarian cancers with rapid progression and poor outcome as resistance to anti-angiogenic therapy develops. Despite therapy, the metastatic progression of aggressive ovarian cancer is a spectacularly selective function of tumor cells aided and abetted by the immune, mesenchymal and angiogenic components of the tumor microenvironment (TME) that enforces several pro-metastatic event(s) via direct and indirect interactions with stromal immune cells, cancer-associated fibroblasts (CAFs), and vascular endothelial cells. Since transdifferentiation of tumor endothelium is one of the major sources of CAFs, we hypothesized that ovarian CAF plays a critical role in resisting anti-angiogenic effects via direct crosstalk with endothelium and hence plays a direct role in the development of resistance to anti-angiogenic drugs. To test the hypothesis, we set up a hybrid ex vivo model for co-culture comprising Patient-Derived ex vivo primary CAFs from ovarian tumor samples and human umbilical vein endothelial cells (HUVEC). Patient-Derived CAFs were characterized by the mRNA and protein expression of positive (SMA, S100A4, TE-7, FAP-A, CD90/THY1), negative (EpCAM, CK 8,18, CD31, CD44, CD45), functional (PDGFRA, TGFB1, TGFB2, TGFRA) and immunological markers (PD-L1, PD-L2, PD-1) associated with CAFs by qRT-PCR, flow cytometry, Western blot, and ICC. Data from our HUVEC-on-CAF ex vivo Hybrid Co-Culture (HyCC) study demonstrate the pro-angiogenic effect of Patient-Derived ovarian CAFs by virtue of their ability to resist the effect of anti-angiogenic drugs, thereby aiding the development of resistance to anti-angiogenic drugs. Ascertaining direct experimental proof of the role of CAFs in developing resistance to specific anti-angiogenic drugs will provide an opportunity to investigate new drugs for counteracting CAF resistance and "normalizing/re-educating" TME in aggressive ovarian cancers. Our data provide a unique experimental tool for the personalized testing of anti-angiogenic drugs, positively predicting the development of future resistance to anti-angiogenic drugs well before it is clinically encountered in patients. Full article
(This article belongs to the Special Issue Arteriogenesis and Angiogenesis: Molecular Mechanisms and Therapies)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 666 KiB  
Review
SARS-CoV-2 and Endothelial Cells: Vascular Changes, Intussusceptive Microvascular Growth and Novel Therapeutic Windows
by Antonio Giovanni Solimando, Donatello Marziliano and Domenico Ribatti
Biomedicines 2022, 10(9), 2242; https://doi.org/10.3390/biomedicines10092242 - 09 Sep 2022
Cited by 6 | Viewed by 1898
Abstract
Endothelial activation in infectious diseases plays a crucial role in understanding and predicting the outcomes and future treatments of several clinical conditions. COVID-19 is no exception. Moving from basic principles to novel approaches, an evolving view of endothelial activation provides insights into a [...] Read more.
Endothelial activation in infectious diseases plays a crucial role in understanding and predicting the outcomes and future treatments of several clinical conditions. COVID-19 is no exception. Moving from basic principles to novel approaches, an evolving view of endothelial activation provides insights into a better knowledge of the upstream actors in COVID-19 as a crucial future direction for managing SARS-CoV-2 and other infections. Assessing the function of resting and damaged endothelial cells in infection, particularly in COVID-19, five critical processes emerged controlling thrombo-resistance: vascular integrity, blood flow regulation, immune cell trafficking, angiogenesis and intussusceptive microvascular growth. Endothelial cell injury is associated with thrombosis, increased vessel contraction and a crucial phenomenon identified as intussusceptive microvascular growth, an unprecedented event of vessel splitting into two lumens through the integration of circulating pro-angiogenic cells. An essential awareness of endothelial cells and their phenotypic changes in COVID-19 inflammation is pivotal to understanding the vascular biology of infections and may offer crucial new therapeutic windows. Full article
(This article belongs to the Special Issue Arteriogenesis and Angiogenesis: Molecular Mechanisms and Therapies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop